fda bpc-157 compounding category 2 list Exciting news for peptides coming out of today's committee hearing! The Pharmacy Advisory Committee voted 8-6 to recommend adding BPC- 157 to the 503A Bulks for use in compounding for Updated 2026 FDA Category 2
Updated 2026 FDA Category 2 peptide list As the science and regulations continue to develop, it's important to work with providers who stay informed and prioritize safe, medically guided protocols. At Category 1 vs. Category 2. The FDA's peptide update, explained. Category 2 peptides are on the FDA's difficult to compound list, which effectively blocks licensed pharmacies from producing them. Category 1 means BPC 157 Legal Status: FDA Regulations and Compounding BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) FDA Adds Several Peptides to Category 2 Bulks List, Restricting Them From Compounding Restore Health Consulting
Pay in 4 interest-free payments of $6.45 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

